JP2021523117A - 慢性蕁麻疹を処置するための方法および組成物 - Google Patents

慢性蕁麻疹を処置するための方法および組成物 Download PDF

Info

Publication number
JP2021523117A
JP2021523117A JP2020561727A JP2020561727A JP2021523117A JP 2021523117 A JP2021523117 A JP 2021523117A JP 2020561727 A JP2020561727 A JP 2020561727A JP 2020561727 A JP2020561727 A JP 2020561727A JP 2021523117 A JP2021523117 A JP 2021523117A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020561727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523117A5 (https=
JPWO2019213468A5 (https=
Inventor
クリストファー ロバート ベビントン，
クリストファー ロバート ベビントン，
ネナド トマセヴィック，
ネナド トマセヴィック，
ヘンリック ラスムッセン，
ヘンリック ラスムッセン，
Original Assignee
アラコス インコーポレイテッド
アラコス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス インコーポレイテッド, アラコス インコーポレイテッド filed Critical アラコス インコーポレイテッド
Publication of JP2021523117A publication Critical patent/JP2021523117A/ja
Publication of JP2021523117A5 publication Critical patent/JP2021523117A5/ja
Publication of JPWO2019213468A5 publication Critical patent/JPWO2019213468A5/ja
Priority to JP2024022749A priority Critical patent/JP2024045612A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020561727A 2018-05-04 2019-05-03 慢性蕁麻疹を処置するための方法および組成物 Withdrawn JP2021523117A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022749A JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US62/667,242 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US62/788,719 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US62/797,817 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US62/803,211 2019-02-08
US201962806657P 2019-02-15 2019-02-15
US62/806,657 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022749A Division JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2021523117A true JP2021523117A (ja) 2021-09-02
JP2021523117A5 JP2021523117A5 (https=) 2022-05-13
JPWO2019213468A5 JPWO2019213468A5 (https=) 2022-05-13

Family

ID=68386174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561727A Withdrawn JP2021523117A (ja) 2018-05-04 2019-05-03 慢性蕁麻疹を処置するための方法および組成物
JP2024022749A Pending JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022749A Pending JP2024045612A (ja) 2018-05-04 2024-02-19 慢性蕁麻疹を処置するための方法および組成物

Country Status (11)

Country Link
US (1) US20210246205A1 (https=)
EP (1) EP3788078A4 (https=)
JP (2) JP2021523117A (https=)
KR (1) KR20210005245A (https=)
CN (1) CN112384535A (https=)
AU (1) AU2019262167A1 (https=)
BR (1) BR112020022236A2 (https=)
CA (1) CA3099338A1 (https=)
MX (1) MX2020011377A (https=)
SG (1) SG11202010911WA (https=)
WO (1) WO2019213468A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501744A (ja) * 2013-12-09 2017-01-19 アラコス インコーポレイテッド 抗ヒトシグレック−８抗体およびその使用の方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501744A (ja) * 2013-12-09 2017-01-19 アラコス インコーポレイテッド 抗ヒトシグレック−８抗体およびその使用の方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HISTORY OF CHANGES FORSTUDY: NCT03436797，CLINICALTRIALS.GOV ARCHIVE[ONLINE]，2018年04月05日，[RETRI, JPN6023017235, ISSN: 0005176853 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用

Also Published As

Publication number Publication date
MX2020011377A (es) 2020-11-24
CN112384535A (zh) 2021-02-19
EP3788078A1 (en) 2021-03-10
BR112020022236A2 (pt) 2021-02-02
CA3099338A1 (en) 2019-11-07
KR20210005245A (ko) 2021-01-13
US20210246205A1 (en) 2021-08-12
WO2019213468A1 (en) 2019-11-07
JP2024045612A (ja) 2024-04-02
EP3788078A4 (en) 2022-03-02
AU2019262167A1 (en) 2020-12-10
SG11202010911WA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP6963577B2 (ja) 抗シグレック−８抗体およびその使用の方法
JP2017501744A5 (https=)
KR20200015511A (ko) 염증성 위장 장애를 치료하기 위한 방법 및 조성물
JP2017507945A (ja) シグレック−８関連疾患を処置するための方法および組成物
JP2022520105A (ja) マスト細胞性胃炎、マスト細胞性食道炎、マスト細胞性腸炎、マスト細胞性十二指腸炎、および／またはマスト細胞性胃腸炎を処置するための方法および組成物
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
US20230406920A1 (en) Anti-siglec-8 antibody formulations
US20220380460A1 (en) Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
WO2024043940A1 (en) Methods and compositions for treating atopic dermatitis
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта
EA045206B1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240308

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240404

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240410